Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07140393
PHASE1/PHASE2

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.

Official title: An Open, Multicenter Phase IB/II Clinical Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2025-10

Completion Date

2028-10

Last Updated

2025-08-24

Healthy Volunteers

No

Conditions

Interventions

DRUG

HRS-4508+ Capecitabine

HRS-4508+ Capecitabine

DRUG

HRS-4508+ Trastuzumab

HRS-4508+ Trastuzumab

DRUG

HRS-4508+ Trastuzumab+ Pertuzumab

HRS-4508+ Trastuzumab+ Pertuzumab

DRUG

HRS-4508+ Trastuzumab+ Capecitabine

HRS-4508+ Trastuzumab+ Capecitabine

DRUG

Trastuzumab+ Capecitabine

Trastuzumab+ Capecitabine

DRUG

HRS-4508+A1811

HRS-4508+A1811

Locations (1)

Cancer Hospital Chinese Academy of Medical Science

Beijing, Beijing Municipality, China